

## GUIDELINES

## 2016 European guideline for the management of vulval conditions

W.I. van der Meijden,<sup>1,\*</sup> M.J. Boffa,<sup>2</sup> W.A. ter Harmsel,<sup>3</sup> G. Kirtschig,<sup>4</sup> F.M. Lewis,<sup>5</sup> M. Moyal-Barracco,<sup>6</sup> G.S. Tiplica,<sup>7</sup> J. Sherrard<sup>8</sup>

<sup>1</sup>Department of Dermatology, Beatrixziekenhuis, Gorinchem, The Netherlands

<sup>2</sup>Department of Dermatology, Sir Paul Boffa Hospital, Floriana, Malta

<sup>3</sup>Department of Gynaecology, Roosevelt kliniek, Leiden, The Netherlands

<sup>4</sup>University Hospital of Tübingen, Tübingen, Germany

<sup>5</sup>St John's Institute of Dermatology, Guy's and St Thomas' Hospital, London and Frimley Health NHS Trust, London, UK

<sup>6</sup>Department of Dermatology, Tarnier-Cochin Hospital, Paris, France

<sup>7</sup>Dermatology 2, Colentina Clinical Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania

<sup>8</sup>Department of Sexual Health, Churchill Hospital, Oxford, UK

\*Correspondence: W.I. van der Meijden. E-mail: vandermeijdenwim@gmail.com

### Abstract

Vulval conditions may present to a variety of clinicians, such as dermatologists, gynaecologists and general practitioners. Women with these conditions are best managed by a multidisciplinary approach, which includes clear referral pathways between disciplines or access to a specialist multidisciplinary vulval service. Informed consent is a prerequisite for all examinations, investigations and treatments. Consent is particularly important for intimate examinations of the anogenital area, and a chaperone should be offered in all cases. All efforts should be made to maintain a patient's dignity. Depending on symptoms and risk factors, screening for sexually transmitted infections (STI) should be considered. If the patient presents with vulval itch, particularly if also complaining of increased vaginal discharge, vulvovaginal candidiasis should be excluded. Sexual dysfunction should be considered in all patients with vulval complaints, either as the cause of the symptoms or secondary to symptoms, and assessed if appropriate. This guideline covers several aspects, such as diagnosis and treatment, of the more common vulval conditions (relatively) often encountered at vulval clinics, i.e. vulval dermatitis (eczema), psoriasis, lichen simplex chronicus, lichen sclerosus, lichen planus, vulvodynia and vulval intraepithelial neoplasia (VIN).

Received: 23 July 2016; Accepted: 14 December 2016

### Conflicts of interest

None declared.

### Funding Sources

None declared.

### Scope

This guideline covers the more common conditions affecting the vulva:

- 1 Vulval dermatitis (eczema)
- 2 Psoriasis
- 3 Lichen simplex chronicus
- 4 Lichen sclerosus
- 5 Lichen planus
- 6 Vulvodynia
- 7 Vulval intraepithelial neoplasia (VIN)

### General advice for delivery of vulval care

Vulval conditions may present to a variety of clinicians including Dermatologists, Genitourinary Medicine Physicians,

Gynaecologists and Primary Care Physicians or General Practitioners (GP). Investigations and management span across this spectrum, so women with vulval conditions are best managed by a multidisciplinary approach, which includes clear referral pathways between disciplines or access to a specialist multidisciplinary vulval service. There should also be access to clinico-pathological services to allow discussion and review of histology results.

### Physical examination of the patient

Informed consent is a prerequisite for all examinations, investigations and treatments. Consent is particularly important for intimate examinations of the anogenital area, and a chaperone should be offered in all cases, and this offer should be

documented clearly in the patient records. The proposed examination should be adequately explained to the patient before they undress. All attempts should be made to maintain patients' dignity, providing privacy to dress and undress, and keeping them covered as much as possible. Appropriate facilities and equipment for investigations should be available prior to commencing the examination. The room should be well lit, private and soundproofed, with a suitable examination couch of adjustable height.<sup>1</sup>

Dermatoses and STIs may coexist or a woman with a pre-existing dermatosis may contract an STI. Screening for sexually transmitted infections (STI) should be considered in all patients, depending on symptoms and risk factors. If the patient presents with vulval itch, particularly with increased discharge, vulvovaginal candidiasis should be excluded. If the symptoms are not relieved by anticondoidal treatment, especially if cultures are negative for candida, then a full genital examination should be undertaken and other causes considered. Possible alternate diagnoses include lichen sclerosus, lichen planus, lichen simplex chronicus, psoriasis or a neoplastic condition (particularly HPV-related vulval intra-epithelial neoplasia in young women). Sexual dysfunction should be considered in all patients, either as the cause of the symptoms or developed secondary to the symptoms, and assessed if appropriate.

Cutaneous disorders may be the initial sign of HIV-related immunosuppression, and many associated skin diseases are more severe in this group. With the onset of immunosuppression, non-specific skin changes occur, such as common disorders with atypical clinical features, including numerous hyperkeratotic warts, treatment-resistant seborrhoeic dermatitis, and new or severe psoriasis. HIV testing should be considered in all patients, but especially in these presentations.

Other conditions where STI testing should be specifically considered, is when genital ulcers are present, even in the presence of a dermatosis that causes ulceration. In these cases testing for herpes simplex and syphilis is recommended. Additionally, where ulcerative lesions fail to heal with standard treatment, investigations to exclude concurrent STIs should be undertaken.

### General advice for all vulval conditions

(see related IUSTI patient information leaflet on <http://www.iusti.org/regions/Europe/PatientInformation.htm>)

- Avoid contact with soap, shampoo and bubble bath. Simple emollients can be used as a soap substitute and general moisturizer
- Avoid tight fitting garments which may irritate the area
- Avoid use of spermicidally lubricated condoms
- Patients should be given a detailed explanation of their condition, with particular emphasis on any long-term health implications, which should be reinforced by giving them clear and accurate written information about the condition

- Consent should be sought for the patient's GP to be informed about the diagnosis and management.

### Topical treatments

- Ointment bases are preferably used on the anogenital skin, because of the reduced need for preservatives in an ointment base, and hence less risk of a secondary contact allergy. Furthermore, cream bases may sting as they contain more water. Regular application of a barrier emollient to the affected areas may protect against local irritants, e.g. urine and menstrual blood.

### Sexual partners

- Partner tracing is not required unless screening detects a sexually transmitted infection.

### Vulval Dermatitis (Eczema)

Dermatitis (also named 'eczema') is an inflammatory reaction characterized histologically by spongiosis, variable acanthosis and a superficial dermal lymphohistiocytic inflammatory infiltrate. The main symptom is itch. Exogenous and endogenous factors can be involved in aetiology.

There is a danger in labelling any erythematous pruritic condition as dermatitis or eczema. Therefore, it is best practice to use the specific diagnosis instead of using these terms, namely atopic dermatitis or irritant/allergic contact dermatitis.<sup>2</sup>

### Aetiology

*Atopic dermatitis* There is increasing evidence that this is due to a defect in the barrier function of the skin.<sup>3</sup> In many atopic individuals, the genital area is spared, but vulval lichen simplex chronicus may be a manifestation of atopic dermatitis, either as isolated vulval disease or in association with disease at other sites.<sup>4</sup>

*Irritant contact dermatitis* This is the commonest type of eczema to affect the vulva. The vulval epithelium is less efficient as a barrier than skin elsewhere<sup>5</sup> and is in contact with moisture, sweat and urine and prone to friction. Cleansers, fragrances, lubricants and many other topical preparations can exacerbate the symptoms. Irritant dermatitis is a particular problem in those with urinary incontinence.

*Allergic contact dermatitis* This is a type IV delayed hypersensitivity reaction, where the individual has developed an allergy to a product applied topically. These are commonly fragrances, antibiotics, local anaesthetics and components of some topical treatments.

*Seborrhoeic dermatitis* This is an inflammatory, desquamative dermatosis affecting the scalp, face and more rarely, the trunk.

Seborrhoeic dermatitis and psoriasis may be associated and have similar pathology. Yeast organisms on the skin may have a role in the development of seborrhoeic dermatitis in predisposed individuals.<sup>6</sup> This form of dermatitis rarely affects the vulva and does not have specific features. In contrast to vulval psoriasis, no specific clinical features of seborrhoeic dermatitis are recognized on the vulva and there is debate about whether this condition exists on the vulva. Therefore, this diagnosis should be made only after exclusion of all other causes of vulval erythema.

### Symptoms

- Pruritus
- Soreness
- Pain

### Signs

- Erythema – this is frequently symmetrical, affecting the labia majora and minora, and extending to the perianal skin and gluteal cleft. In allergic contact dermatitis, this may extend to the thighs.
- Excoriations
- Erosions – if acute
- Serous discharge with oozing and crusting, especially if secondary infection is present
- Lichenification – if chronic

### Complications

- Secondary infection
- Development of lichen simplex chronicus

### Diagnosis

The diagnosis is usually clinical, based on the clinical history and physical signs. It is helpful to check the rest of the skin for other features of atopic or seborrhoeic dermatitis. The main differential diagnoses are as follows:

- Psoriasis: there are usually well-defined plaques and fissuring is a common feature, which is not seen frequently in dermatitis. Full skin examination, including the scalp and nails, can give helpful diagnostic clues.
- Candidiasis: this can give a symmetrical, ill-defined erythema, sometimes in the absence of vaginal symptoms. A vulval swab will help to assess this diagnosis.
- Tinea cruris: although rare in women, this should be suspected if there is well-defined, annular or circinate erythema with a papular or pustular edge with peripheral scaling.
- Streptococcal A infection: as a primary or secondary event (superinfection of a pre-existing dermatosis), this can present with symmetrical erythema.

### Investigation

A biopsy is rarely necessary but should be performed if there are atypical features or failure to respond to treatment (IV, C).

Patch testing (III, B) is useful if an allergic contact dermatitis is suspected, but is not necessary for all types of dermatitis. Patch testing should be performed in a clinic competent in this investigation and interpretation of the results. In addition to the standard series of allergens, any patient with a suspected vulval allergic contact dermatitis should be tested to medicaments, preservatives and specific products used on the vulva, at the appropriate dilutions.<sup>7,8</sup> The relevance of the results must be assessed carefully, as a positive test does not necessarily mean that the tested product is responsible for the vulval rash. Conversely, a negative test cannot completely prove the innocence of a topically applied product.

Mycological and bacteriological specimens will exclude candidiasis, tinea and bacterial infection.

### Management

- 1 Avoidance of irritants and possible allergens may be precipitating factors, e.g. cleansers, fragrances and wet wipes (IV, C). If urinary incontinence is present, then this should be addressed and referral to uro-gynaecology is helpful.
- 2 Use of a bland emollient as a soap substitute, e.g. emulsifying ointment (IV, C).
- 3 A topical steroid such as 1% hydrocortisone ointment can be used for mild cases and mometasone furoate or betamethasone valerate 0.025% for more severe disease. This can be applied once daily for 7–10 days until the symptoms and signs settle and can then be used as needed for any recurrent symptoms (IV, C).
- 4 Treat any co-existing infection with a combination steroid/antifungal or steroid/antibacterial (IV, C).
- 5 A sedating antihistamine given at night should reduce the damage inflicted by scratching. Calcineurin inhibitors (IV, C) (topical tacrolimus and pimecrolimus) can be tried for resistant cases, but their use is limited by stinging on application.<sup>9</sup>

### Follow-up

Follow-up is not required routinely, but patients who need to use a more potent topical steroid or who have problems in controlling their symptoms should be reviewed.

### Patient information

Patients should be given an explanation of their condition and the potential for a recurrence of symptoms. Advice about hygiene practices that can exacerbate the problem can be linked with useful patient information websites.

## Vulval Psoriasis

### Aetiology

Psoriasis is an immune-mediated disease with genetic predisposition. Several trigger factors are described (some of them

present in populations at risk for STI)<sup>10</sup>: infections (e.g. streptococcal, HIV), smoking, alcohol excess, physical factors (e.g. tattoos, piercing) and medication (e.g. systemic steroids, beta-blockers, lithium, non-steroidal anti-inflammatory drugs).

### Clinical features

Genital skin is affected in 29–46% of patients with psoriasis.<sup>11</sup> Vulval psoriasis can be present in patients with psoriasis vulgaris as localized disease (2–5% of cases<sup>12</sup>) or in a disseminated form (affecting also the extensor regions or the gluteal cleft). Vulval involvement can occur in patients with inverse psoriasis (rare cases with involvement of the flexural folds and genitalia). Generalized pustular psoriasis (a rare form of exudative psoriasis) can start spreading from the genital area. Impetigo herpeticiformis is a rare dermatosis of pregnancy with similar pustular lesions that develop from the intertriginous areas (including vulva). Typical onset is during the last trimester of pregnancy with rapid resolution in the postpartum period. Clinically and histologically, it is consistent with pustular psoriasis. Erythrodermic psoriasis is an uncommon form of psoriasis that can cover more than 90% of body surface and be present in the vulval region.

### Symptoms

- Vulval itch, pain or burning sensation can be present.

### Signs

- Monomorphic, symmetrical eruption of erythematous plaques on the vulva. The lesions are well defined, with round margins. Fine silvery scales can be present, but are less common at the genitals than at other locations. Lesions can extend to adjacent regions (inguinal, perineal, pubic). Sometimes painful fissures can be present.<sup>13</sup>
- In rare cases, pustular lesions can occur on erythematous macules that spread from the vulva and other flexural folds to the rest of the body.

### Associated disorders

Psoriatic arthritis<sup>14</sup> occurs in 15–30% of patients with psoriasis vulgaris or exudative psoriasis. Cardiovascular disease, hypertension, malignancy, diabetes, metabolic syndrome, inflammatory bowel disease or autoimmune diseases can also be associated with psoriasis.

### Diagnosis

The diagnosis can usually be made from the history combined with the physical examination, which should include extra-genital sites where psoriasis is common such as the scalp, nails, natal cleft and umbilicus.

### Investigation

The histopathological examination is characteristic: parakeratosis, Munro micro-abscesses (neutrophils in the stratum

corneum), absent granular cell layer, epidermal hyperplasia, frequent mitoses in the basal cell layer and dilated tortuous capillaries in the dermal papillae.<sup>15</sup>

Investigations for possible associated inflammatory diseases should be considered.

### Management

**General advice** The patient should avoid all known trigger factors including scented detergents, synthetic underwear and tight pants.<sup>13</sup>

Topical treatment is indicated for localized vulval psoriasis. In patients with disseminated or generalized lesions of psoriasis, the systemic therapy is also effective for the genital lesions – this treatment is described in other guidelines.<sup>16</sup>

Due to possible local adverse reactions (mainly irritant), it is recommended to avoid the use of anthralin, tazarotene and ultraviolet therapy when treating vulval psoriasis (II, B).<sup>13</sup>

**Recommended Regimens** Treatment will reduce the thickness of the lesions, the degree of erythema and remove scales. All therapeutic possibilities should be presented to obtain a tailored therapy that is acceptable to the patient. If pubic hair is present, the vulval lesions will be better treated with solutions, foams or gels.<sup>17</sup> To cover the whole genital area, 0.5 fingertip units should be sufficient.<sup>18</sup>

- 1 Topical corticosteroids prescribed in sequential or rotational therapeutic regimens (I, B)<sup>19–21</sup>; mid potency topical steroids followed by low potency topical steroids.
- 2 Topical vitamin D analogues in mono-therapy or in combination with topical corticosteroids (I, B).<sup>22,23</sup>
- 3 Coal tar preparations (e.g. 1–5% liquor carbonis detergens in aqueous cream) in mono-therapy or in combination with topical corticosteroids (III).<sup>22,24</sup>

Emollients are recommended to reduce local irritation induced by other topical treatment and to maintain the therapeutic results (I, B).<sup>22,25</sup>

**Unlicensed treatments** Topical calcineurin inhibitors (tacrolimus, pimecrolimus) are reported to be effective in vulval psoriasis (III). Contact dermatitis and local infections (mycotic, viral) can be induced.<sup>21,26</sup>

Dapsone is reported to be effective in vulval pustular psoriasis (100 mg/day, 1 month) in combination with topical treatment (IV).<sup>27</sup>

### Pregnancy and breastfeeding

Emollients are considered safe during pregnancy and lactation.<sup>17</sup> Pregnant and breastfeeding mothers were excluded from the above clinical studies involving topical corticosteroids and vitamin D analogues. There is no information on medication excretion in breast milk. Topical calcineurin inhibitors are not

licensed in pregnancy and in breastfeeding mothers. Topical coal tar usage for short periods of time during pregnancy is considered to only have a small risk.<sup>17,28</sup>

### Follow-up

Active disease should be assessed as clinically required. Stable disease should be reviewed after 1–3 months.

## Lichen Simplex Chronicus

Anogenital lichen simplex chronicus is a common condition. However, the incidence and prevalence have not been established properly. It is estimated to occur in approximately 0.5% of the Western European and American population. In vulval clinics, it may comprise 10–35% of patients seen. The condition usually develops in mid- to late-adult life.<sup>4</sup>

### Aetiology

Anogenital lichen simplex chronicus is most often encountered in persons with an atopic diathesis: up to 75% of patients have a personal or immediate family history of atopy<sup>4</sup>

- Primary or idiopathic lichen simplex chronicus develops on a background of normal vulval skin, usually in atopics
- Secondary lichen simplex chronicus is superimposed on itchy vulval dermatoses, such as eczema, psoriasis, lichen sclerosus or a fungal or yeast infection.

The condition is triggered by psychological distress, such as anxiety, depression and obsessive compulsive disorder, and local environmental factors, such as heat, sweating, dryness of the skin, friction and harsh skincare products. Other predisposing conditions are those which cause generalized pruritus, e.g. uraemia, liver disease and thyroid disease. Although probably rare, it may sometimes be worthwhile to consider neuropathic itch as a possible cause. This could be associated with sacral spinal compression, postherpetic neuralgia and diabetic neuropathy.<sup>29</sup> The itch–scratch–itch cycle plays a pivotal role in maintaining chronicity of the condition.

### Symptoms

- Chronic, or intermittent severe pruritus, usually occurring in the evening or during sleep
- Burning and soreness, in case of vulval erosions or ulcers
- Dyspareunia, in case of vulval erosions or ulcers.

### Signs

- Poorly demarcated, lichenified plaques, maybe more marked on the side opposite to the dominant hand; skin may feel leathery
- Erosions, ulcers, fissures
- Hyper-, hypo- or depigmented skin areas
- Broken hair in areas of scratching and rubbing.

### Complications

- Secondary infection of vulval skin lesions
- Chronic, deep scratching and gouging may lead to severe and irreversible architectural damage<sup>4</sup>
- Vulval lichen simplex chronicus does *not* seem to be associated with a higher risk of squamous cell cancer<sup>30</sup>

### Diagnosis

#### History taking

- Indications of atopic disease in patient or first-degree relatives?
- Skin problems elsewhere? If so, has a diagnosis been made?

Clinical examination is usually sufficient to make a diagnosis. The presence of skin disease elsewhere may be helpful in establishing a differential diagnosis.

### Investigation

- Biopsy (IV, C). Seldom necessary. Only in case of uncertainty about the diagnosis. It may be difficult to distinguish lichen simplex chronicus from psoriasis on histopathological grounds
- Screening for infection if indicated (e.g. *Staphylococcus aureus*, *Candida albicans*)
- Dermatological referral for patch testing if contact allergy is suspected<sup>2</sup> (III,B)
- Serum ferritin<sup>2</sup> (IV, C). In case of suspicion of low iron store, e.g. in women who are vegetarian or donate blood.

### Management

#### Recommended regimens

- Improvement of skin barrier function (saline soaks, followed and later replaced by lubricants – any unperfumed cream will do, petroleum-based lubricants too greasy)<sup>4</sup> (IV,C)
- Identifying underlying disease, if any
- In severe disease, superpotent topical corticosteroid, e.g. clobetasol propionate 0.05% ointment, once or twice daily (IV,C)
- In case of night-time scratching: mildly sedative antihistamine (e.g. hydroxyzine) or tricyclic (e.g. amitriptyline).<sup>4,31</sup>

#### Alternative regimens

- Topical calcineurin inhibitors twice daily for up to 12 weeks (pimecrolimus 1% cream, tacrolimus 0.1% ointment) may be used as unlicensed, second-line treatment<sup>31,32</sup>
- Narrow band ultraviolet B, delivered by comb-like instrument<sup>33</sup> (III,B)
- Silk fabric underwear may reduce the need for topical corticosteroids<sup>34</sup> (Ib,A).

### Follow-up

- Mild disease: as clinically required
- Severe disease (i.e. when using potent topical corticosteroids): 4 weeks, then as required (IV,C).

### Lichen Sclerosus

Lichen sclerosus (LS) is an inflammatory skin disease that involves the anogenital area more often than other cutaneous sites; typically, it does not affect the vagina and very rarely involves the oral mucosa. It is mainly seen in adult women, but children may be affected. The signs in young girls may be difficult to distinguish from those of sexual abuse. LS is probably underdiagnosed. In females, the course is usually chronic, but should be diagnosed as soon as possible, as early treatment prevents scarring and possibly malignant change. Spontaneous remission can be observed.

### Aetiology

LS is an inflammatory dermatosis of unknown aetiology. A genetic predisposition is implicated. A positive family history is observed in about 10% of patients with vulval LS. An increased incidence of autoantibodies to the extracellular matrix protein 1 and autoantibodies to BP180 antigen are reported. Their significance is not known, but may support the idea of LS being a (humoral) autoimmune disease.<sup>35,36</sup> Oxidative DNA damage was detected throughout LS biopsies, indicating that oxidative damage to lipids, DNA and proteins may contribute to sclerosis, autoimmunity and carcinogenesis in LS. The possible role of TP53 mutations in the development of vulval cancer in LS is postulated.

### Symptoms

- Itch
- Soreness
- Dyspareunia or apareunia
- Urinary symptoms (pain, poor urinary stream)
- Other symptoms, e.g. constipation, can occur if there is perianal involvement, in particular in children
- Can be asymptomatic

### Signs

- Pale, white hypertrophic or atrophic areas (vulva, perianal, extragenital)
- Hyperkeratosis
- Sclerosis
- Slight erythema/redness
- Purpura (ecchymosis) is common
- Fissuring anogenitally
- Erosions, but blistering is very rare
- Changes may be localized or in a 'figure of eight' distribution, including the perianal area

- Scarring may lead to loss of architecture (resorption of the labia minora, fusing in the midline with burying, but not loss of the clitoris)
- Follicular plugging (extragenital)

### Complications

- Loss of self-esteem (concern about the clitoral appearance)
- Development of squamous cell carcinoma (actual risk <5%)<sup>37</sup>
- Development of clitoral pseudo-cyst
- Sexual dysfunction
- Urinary dysfunction
- Dysaesthesia

### Diagnosis

Characteristic clinical appearance. In typical cases, a biopsy may not be needed, but many clinicians prefer to take a biopsy at presentation. A biopsy should be performed if the clinical diagnosis is uncertain, dysplasia/carcinoma is suspected or there is failure of first-line treatment. Clinical and pathological correlation is essential. In early disease, histology can be non-specific.

Key histopathological features (biopsy has to be taken from a typical lesion)<sup>38</sup>:

- Hyperkeratosis
- Atrophic epidermis
- Basal hydropic degeneration +/- pigmentary incontinence
- Lymphohistiocytic infiltrate in hyaline band with loss of elastic tissue in upper dermis
- Follicular plugging in hair bearing skin

### Further investigations

Investigation for autoimmune disease if clinically indicated, because some diseases (e.g. thyroid disease, pernicious anaemia, vitiligo, diabetes mellitus) are associated with LS in females (IV,C).<sup>36</sup> These conditions may be asymptomatic. Skin swabs for bacterial, fungal or viral infection are only useful to exclude co-existing infection, if there are symptoms or signs suggestive of this. Patch testing: rarely required and only if secondary (medicament) allergy is suspected. The advice of a dermatologist should be sought.

### Management

**General advice** Patients should be informed about the condition and given written information. Patients should be made aware of the small risk of neoplastic change, although this may be less in well-controlled LS.<sup>39</sup> They should be advised to contact the doctor if they notice a change in appearance (e.g. lump, ulceration or hardening of skin), or if there is a major change in symptoms.

LS needs to be treated. About 10% of patients have no itch, but will have clinical signs of LS and should also be treated (IV,



C). After initial treatment (usually 3 months), some patients will become asymptomatic with few remaining signs of LS, others may be left with irreversible scarring. There is debate amongst specialists about further treatment once symptoms and signs are suppressed by the initial treatment. This is because it can be difficult to decide whether there is still active disease. However, as it is known that LS may progress and lead to more scarring despite the lack of symptoms after initial treatment, some propose continuous, preventive treatment for many years to prevent progression (IV, C). Lee *et al.* in a recent series, with a mean follow-up of 5 years, showed that continuous treatment with individually chosen applications of a topical steroid will prevent symptoms, further scarring and carcinoma development in 58% vs. 93.3%, 40% vs. 3.4% and 0% vs. 4.7%, respectively.<sup>39</sup> Emollients may give symptom relief after initial steroid treatment (IIB B).<sup>40</sup>

**Specific treatment** Potent<sup>41</sup> or ultra-potent topical steroids,<sup>42</sup> e.g. mometasone furoate or clobetasol propionate are first-line recommendations for genital LS (Ib, A).

**Recommended regimen** Various regimens are used; one of the most common being daily use of potent to ultra-potent topical steroids (usually once daily) for 3 months. Others use the steroid daily for 1 month, then alternate days for 1 month, twice weekly for 1 month (this may be preferred in children to avoid skin atrophy) with review at 3 months. Twice daily application may occasionally be of additional benefit in resistant LS.

**Maintenance treatment** Proactive maintenance therapy with twice-weekly application of mometasone furoate 0.1% ointment is effective and safe in maintaining remission, and may help to prevent malignant change (Ib, A)<sup>39,43</sup>; 30 g of an ultra-potent steroid should last at least 3 months.

**Treatment of superinfection** An ultra-potent or potent topical steroid preparation combined with antibacterial and antifungal agents, e.g. gentamycin or fusidic acid and nystatin or azole antifungals or an alternative preparation that combats secondary infection may be appropriate if secondary infection is a concern. These should only be used for a short period of time to clear infection (IV, C).

**Allergies to topical preparations** Allergies to any compound (also steroids) of a topical preparation may occur after long-term use. In case of a waning effect of a previously good treatment, allergy testing may be indicated.

**Alternative second-line treatments** Topical calcineurin inhibitors are not licensed for the treatment of LS. However, the efficacy of topical tacrolimus 0.1% has been demonstrated in the treatment of vulval LS<sup>44</sup> (Ib, A) and when used for 16–24 weeks

in males and females with genital and extra-genital LS<sup>45</sup> (IIB, B). Topical tacrolimus 0.03% ointment appears to be an effective treatment for children with anogenital LS and as maintenance treatment (twice a week), possibly reducing recurrences<sup>46</sup> (III, B). Comparing pimecrolimus 1% cream and clobetasol propionate 0.05% cream, both treatments showed improvement in pruritus and burning/pain after 12 weeks in vulval LS, but clobetasol was found to be superior in improving inflammation<sup>47</sup> (Ib, A). Another study of pimecrolimus showed that 42% of patients were in ‘complete remission’ after 6 months application<sup>45</sup> (IIB, B). Local irritation was the most common side effect with both tacrolimus and pimecrolimus but usually improved after the initial period of use.<sup>48, 49</sup> The long-term risks need to be studied in view of concerns about the possibility of topical immunosuppression increasing risk of malignancy.<sup>50</sup>

Limited data from two small RCTs demonstrate efficacy of systemic retinoids in the treatment of genital LS.<sup>51–53</sup> Retinoids may be considered if standard therapy for LS has failed but should only be given by a dermatologist, experienced in the use of these agents. They are severely teratogenic and effective contraception should start 1 month before treatment and should continue throughout oral retinoid treatment and after until the retinoids have left the patient’s system, i.e. at least 1 month after stopping treatment with isotretinoin or acitretin and at least 2 years after stopping treatment with acitretin (Ib, A). Topical hormonal therapy (progesterone or testosterone preparations) failed to demonstrate efficacy in controlled trials (IIa, B).<sup>42</sup>

Phototherapy is effective in some patients with LS. In vulval LS, UVA1 may be considered if topical corticosteroids have failed. However, the well-documented development of carcinomas after PUVA and UVB gives cause of concern, in particular at the genital site<sup>54,55</sup> (Ib, A).

Surgery in vulval LS should only be used for the treatment of coexistent VIN/SCC or fusion.<sup>56</sup> Disease tends to recur around the scar in females (III, B).

**Clitoral LS** Lichen sclerosus may appear isolated at the clitoral hood; however, often other vulval parts are also affected. Early signs of clitoral LS are swelling of the prepuce; white plaques, fissures and scarring may follow. If the clitoral prepuce is affected by LS, this may lead to fusion of the skin and a burrowed clitoris. Clitoral involvement should be searched for and treated like LS at other genital sites. As mechanical triggers are thought to be important in maintaining LS, e.g. any tight clothing should be avoided. Topical preparations should be massaged in gently. Surgery, to treat fusion, is only indicated in rare situations (e.g. severe problems with self-esteem, sexual function or urination). There is a chance of recurrence after surgery because the inflammatory process may not have ceased. Surgery should only be performed by an experienced surgeon and after careful counselling about the intervention, adverse effects and potential recurrences.

**Extragenital LS** There are fewer studies for the treatment of extragenital LS. UVA1 phototherapy is a potential first-line treatment option<sup>55,57</sup> (Ib, A).

Potent topical steroids and topical calcipotriol, possibly under occlusion, may be tried in extragenital LS<sup>57</sup> (III, B).

### Pregnancy and breastfeeding

- Limited amounts of potent topical steroids are safe to use whilst pregnant or breastfeeding.
- Topical calcineurin inhibitors are not licensed whilst pregnant or breastfeeding.
- Retinoids are severely teratogenic and effective contraception should start 1 month before treatment and should continue throughout oral retinoid treatment and after until the retinoids have left the patient's system, i.e. at least 1 month after stopping treatment with isotretinoin or alitretinoin and at least 2 years after stopping treatment with acitretin. Retinoids should be used with caution in all females of child-bearing age.

### Onward referral criteria

Those with active disease which has not responded adequately to treatment should be referred to a physician specialized in the condition. Any patient who develops differentiated or undifferentiated VIN or an SCC on a background of LS should be seen and followed up by an experienced specialist.

### Follow-up

- After 3 months to assess response to treatment
- Stable disease should be reviewed annually, and this can be performed by the GP in those with well-controlled disease. This must be communicated to the patient and GP by the specialist.
- Patients should be informed that if they notice the development of a lump, sore area, change in symptoms or change in appearance they should seek prompt medical review.

## Lichen Planus

### Aetiology

Lichen planus is an inflammatory disorder with manifestations in skin, hair, nails and genital and oral mucous membranes; more rarely, it affects the lacrimal duct, oesophagus and external auditory meatus. It is an inflammatory condition of unknown pathogenesis, but is probably an immunological response by T cells activated by, as yet, unidentified antigens. Weak circulating basement membrane zone antibodies have been demonstrated in 61% of 56 patients with biopsy-proven erosive lichen planus of the vulva but are of unknown significance.<sup>58</sup> In some cases, there is overlap between lichen planus and lichen sclerosus.<sup>59</sup>

### Symptoms

- Itch/irritation
- Soreness
- Dyspareunia
- Urinary symptoms
- Vaginal discharge
- Can be asymptomatic.

### Signs

The anogenital lesions of lichen planus may be divided into three main groups according to their clinical presentation:

**Classical** Typical papules occur on the keratinized anogenital skin, with or without Wickham's striae, on the inner aspect of the vulva. Hyperpigmentation frequently follows their resolution, particularly in those with dark skin. This type of lichen planus may be asymptomatic. Vulval lesions were found in 19 of 37 women with cutaneous lichen planus, with four of the 19 having had no symptoms.<sup>60</sup>

**Hypertrophic** These lesions are relatively rare and can be difficult to diagnose. They particularly affect the perineum and perianal area, presenting as thickened warty plaques which may become ulcerated, infected and painful. The clinical appearance may mimic malignancy. They are not usually accompanied by vaginal lesions.

**Erosive** This the most common subtype to cause vulval symptoms. The mean age of onset of vulval symptoms in 114 women with erosive lichen planus was 56.9 years.<sup>61</sup> The mucosal surfaces are eroded. At the edges of the erosions, the epithelium is red-to-purple coloured and a pale network of Wickham's striae is sometimes seen. It is important to recognize vaginal involvement in erosive lichen planus (which can occur in isolation) and start treatment early, as it can lead to scarring and complete stenosis. The lesions consist of friable telangiectases with patchy erythema which are responsible for the common symptoms of dyspareunia, postcoital bleeding and a variable discharge, which is often serosanguinous. As erosions heal, synechiae and scarring can develop.<sup>62</sup> This type is also seen in the oral mucosa although synechiae are uncommon. The term 'vulvo-vaginal-gingival syndrome' is used when erosive disease occurs in these three sites. The presenting symptoms are usually pain and soreness.

Diagnostic criteria for vulval erosive lichen planus have been proposed in an international e-Delphi exercise.<sup>63</sup> It is suggested that at least three of the following criteria should be present to make the diagnosis: (i) well-demarcated erosions/erythematous areas at the vaginal introitus; (ii) presence of a hyperkeratotic border to lesions and/or Wickham striae in surrounding skin; (iii) symptoms of pain/burning; (iv) scarring/loss of normal architecture; (v) presence of vaginal inflammation; (vi)



involvement of other mucosal surfaces; (vii) presence of a well-defined inflammatory band involving the dermo-epidermal junction; (viii) presence of an inflammatory band consisting predominantly of lymphocytes; and (ix) signs of basal layer degeneration.

### Complications

- Scarring, including vaginal synechiae.
- Development of squamous cell carcinoma. In one study, the incidence was as high as 3%.<sup>61</sup> Patients with lichen planus-associated squamous cell carcinoma have a high rate of inguinal metastases, recurrent vulvar cancers in diseased mucosa and disease-related death.<sup>64</sup>

### Diagnosis

*Characteristic clinical appearance* Involvement of the vagina excludes lichen sclerosus. Skin changes elsewhere can be helpful, but overlap between lichen planus and lichen sclerosus is described. Immunobullous disorders such as cicatricial mucous membrane pemphigoid and pemphigus can clinically resemble erosive lichen planus.

*Dermoscopy* Specific dermoscopic features that may aid clinical diagnosis include the presence of thick linear irregular vessels arranged diffusely throughout lesions, peripheral Wickham's striae and an intense red background.<sup>65</sup>

*Histology of vulval biopsy* Irregular saw-toothed acanthosis, increased granular layer, basal cell liquefaction and band-like dermal mainly lymphocytic infiltrate.<sup>38</sup>

### Further investigations

- Biopsy is indicated if the diagnosis is uncertain or coexistent, intraepithelial neoplasia/squamous cell carcinoma is suspected. Direct immunofluorescence should be performed if an immunobullous disease is considered in the differential diagnosis. Only 25% are classic on biopsy and clinico-pathological correlation is important.
- Thyroid and other autoimmune disease are only rarely associated with vulval lichen planus. Investigation for autoimmune disease is indicated if there is clinical suspicion of abnormality (IV,C).<sup>66</sup>
- Skin swab: to exclude secondary infection, especially of excoriated lesions.
- Patch testing: if medicament contact allergy suspected.

Whilst a link with hepatitis C and sometimes B has been noted in some (especially Mediterranean) countries, a UK study of 100 women with vulval mucosal lichen planus found no evidence of increased incidence and concluded that routine screening is unnecessary.<sup>67</sup> Nevertheless, screening may still be prudent in populations with a high prevalence of viral hepatitis.

### Management

*General Advice* Patients should be informed about the condition and given written information. Patients should be made aware of the small long-term risk of neoplastic change and advised to seek urgent medical advice if they notice a change in appearance or texture (e.g. lump, hardening of skin or persistent ulceration).

*Treatment* There is only one randomized controlled trial evidence to guide treatment of vulval erosive lichen planus.<sup>68,69</sup>

### Topical Treatment

#### Recommended regimens

- Ultrapotent topical steroids, e.g. clobetasol propionate. (IIb, B) In a study of 114 patients in a vulval clinic, 89 used ultra-potent topical steroids as first-line treatment of whom 75% improved and 54% were symptom-free. However, in only 9% was there resolution of signs of inflammation.<sup>61</sup> There is no evidence on the optimal regimen.
- Maintenance treatment may be required and can either be with weaker steroid preparations or less frequent use of potent steroids.
- Vaginal corticosteroids: Delivery of corticosteroids to the vagina is not easy. A proprietary preparation containing hydrocortisone (Colifoam<sup>®</sup> rectal foam) introduced into the vagina with an applicator is useful. Prednisolone suppositories may be used in more severe cases (IV,C).

#### Alternative regimens

- An ultra-potent topical steroid with antibacterial and antifungal, e.g. clobetasol with neomycin and nystatin or an alternative preparation, e.g. betamethasone with fusidic acid or generic equivalent may be appropriate if secondary infection is a concern. These should only be used for a short period of time to clear infection (IV,C).
- The topical calcineurin inhibitors pimecrolimus and tacrolimus may be effective in vulval lichen planus; pimecrolimus may be better tolerated.<sup>70</sup> In a retrospective series of 16 women with vulval lichen planus, topical tacrolimus effectively controlled symptoms and improved lesions in all but one patient. The effect may be temporary, requiring continued use of tacrolimus, which, however, appears to be safe and effective in controlling disease activity.<sup>71</sup>

*Systemic treatments.* There is no consensus and little evidence base for the use of systemic agents. In the vulvovaginal-gingival syndrome, there is general agreement that azathioprine, dapsone, griseofulvin, chloroquine and minocycline, all tried empirically, are of little or no benefit. Cyclosporin may be considered.

- The retinoid acitretin can be helpful in hypertrophic cases. The drug is severely teratogenic and is absolutely

contraindicated during pregnancy. Pregnancy must be avoided for 2 years after finishing treatment. It should be used with caution in other females of child-bearing age.

- Oral steroids are used, e.g. prednisolone 40 mg/day, tapered off over a few weeks, for severe flares; courses can be repeated as necessary.
- Long-term methotrexate 5–10 mg weekly was used successfully in 11 of 131 patients with vulvovaginal lichen planus<sup>72</sup>
- Mycophenolate mofetil may be effective and worth considering for recalcitrant cases<sup>73,74</sup>

The new biological agents have shown varying results. However, the rising trend of TNF- $\alpha$  inhibitors inducing lichen planus-like eruptions including erosive oral and vulval disease<sup>75</sup> reserves these drugs for only the most recalcitrant cases. Basiliximab was reported to be effective in erosive oral lichen planus, although its use has not been evaluated in vulval disease.<sup>76</sup>

All these potentially toxic therapies need careful monitoring and are best supervised by a dermatologist in the context of a specialized clinic (IV, C).

**Surgery.** Surgery may be necessary for the management of symptomatic vulval and vaginal adhesions and scarring, but is contraindicated in patients with active, inflammatory disease.<sup>77</sup> In a study of 11 women with lichen planus scarring, surgical lysis of vulvovaginal adhesions allowed intercourse in 55% and decreased urination difficulties in 75%. Of the patients, 91% stated they were happy with the surgery and would recommend it to others. However, sexual difficulties may persist even after surgery.<sup>78</sup>

#### **Pregnancy and breastfeeding**

- Topical steroids are safe to use whilst pregnant or breastfeeding.
- Topical calcineurin inhibitors are not licensed whilst pregnant or breastfeeding.<sup>42</sup>
- Retinoids are severely teratogenic and effective contraception should start 1 month before treatment and should continue throughout oral retinoid treatment and after until the retinoids have left the patient's system, i.e. at least 1 month after stopping treatment with isotretinoin or alitretinoin and at least 2 years after stopping treatment with acitretin. Retinoids should be used with caution in all females of child-bearing age.

#### **Onward referral**

Referral to a multidisciplinary vulval clinic is recommended for erosive disease, recalcitrant cases or those in whom systemic therapy is considered.

#### **Follow-up**

- At 2–3 months to assess response to treatment.

- Active disease should be assessed as clinically required. Erosive vulval lichen planus needs long-term specialized follow-up (IV, C).
- Stable disease should be reviewed annually, except in well-counselled patients who control their symptoms well. If review is to be undertaken by the GP, this should be communicated to the patient and GP by the clinic.
- Patients should be advised to seek urgent medical advice if they notice a change in appearance or texture (e.g. lump, hardening of skin or persistent ulceration).

### **Vulvodinia**

According to the 2003 International Society for the Study of Vulvovaginal Diseases (ISSVD) terminology, vulvodinia is defined as 'vulval discomfort, most often described as burning pain, occurring in the absence of relevant visible findings or a specific, clinically identifiable, neurological disorder'.<sup>79</sup> Vulvodinia is also categorized by the ISSVD, as generalized or localized, provoked, unprovoked or mixed (both provoked and unprovoked) (see symptoms).

#### **Aetiology**

Vulvodinia is currently considered as a dysfunctional sensory processing in the central nervous system, involving both central and peripheral pain generators.<sup>80–82</sup> This mechanism is similarly observed in other painful conditions (fibromyalgia, interstitial cystitis/painful bladder, irritable bowel, temporomandibular dysfunction) which have a significant association with vulvodinia.<sup>83,84</sup> A genetic predisposition to both vulvodinia and these other pain conditions is suspected.<sup>85</sup> Triggering or maintaining factors have been identified: candidiasis,<sup>86</sup> psychological disturbances either resulting from the chronic pain or pre-existing to it,<sup>87–89</sup> and pelvic floor muscle dysfunction.<sup>90</sup>

#### **Symptoms**

The mnemonic (memory aide) OPQRST-A can be used to describe and evaluate the vulval discomfort.

**Onset** Candidiasis is frequently an initiating event of vulvodinia (IIB) but any acute painful vulval, urinary or anal condition (e.g. infection, surgical procedure) may precede the occurrence of vulvodinia, especially if these physical events occur in a context of emotional stress (IV).

**Provocation** The discomfort may be either provoked or unprovoked or mixed.

##### **1 Provoked**

- a By sexual contact: penetration (introital dyspareunia) or touch. Introital dyspareunia may be either primary (since the first intercourse) or secondary (occurring after a period of painless intercourse).

- b By non-sexual contact: tampon insertion, tight clothing, sitting position, gynaecological examination
- 2 Unprovoked: the discomfort occurs spontaneously, it is not related to touch.
- 3 Mixed: the discomfort is both spontaneous and aggravated by local contacts (either sexual or non-sexual).

**Quality** Burning is the main symptom, but many other sensations are reported (e.g. tingling, stinging, rawness, irritation). When present, itch is not the predominant symptom.

**Region** The discomfort may be either localized or generalized.

- 1 Generalized: the whole vulva is involved (clitoris, labia minora and majora, vestibule). The patient may also describe the symptoms spreading to the thighs and perianal area.
- 2 Localized: one or several sites are involved. The most frequently involved site is the vestibule (i.e. the introitus), particularly its posterior aspect. This is termed vestibulodynia. Provoked vestibulodynia is the most reproducible subset of vulvodynia. More rarely, the discomfort is localized to other parts of the vulva: labia minora or majora, clitoris (clitorodynia).

**Severity** The severity of the discomfort is highly variable, impacting both daily life (impossible to concentrate on normal activities) and sexual activity (painful sex leading to fear and avoidance, with consequences on the partner and relationship).

**Time** Vulvodynia is a chronic pain condition having usually lasted months or years before the diagnosis is made. The intensity of the discomfort is often variable over time. Significant improvement or complete remission may occur, following treatment, or spontaneously (IIa).<sup>91,92</sup>

**Associated symptoms** Other pain conditions (mentioned before) may be associated, particularly interstitial cystitis/painful bladder<sup>93</sup> (level B). No sphincter disturbance occurs in vulvodynia.

### Signs

Inspection of the vulva reveals no relevant physical findings. This means that the vulva has a normal appearance or that, if a lesion is found, this lesion cannot explain the discomfort (e.g. a wart cannot explain diffuse burning). In provoked vestibulodynia, tenderness is elicited by gentle application of a cotton wool tip on the vestibule. Neurological examination is normal (in particular, there is no perineal anaesthesia).

### Complications

Impact on general well-being, particularly on psychosexual function and relationships.<sup>94</sup>

### Diagnosis

It is a clinical diagnosis based on signs and symptoms.

### Differential diagnosis

- Vulval conditions either inflammatory, infectious or neoplastic responsible for vulval discomfort are detectable by inspection.
- Neurological conditions responsible for perineal pain are suspected on sphincter disturbances and objective neurological abnormalities. Imaging (pelvic and lumbosacral MRI) is indicated in cases of spontaneous generalized vulval pain resistant to treatments (IV).

### Management

**Information** Patients should be given a full explanation of their condition verbally, and then reinforced with written information. Do not cast doubt about the reality of the pain (not 'in the head') and acknowledge its significant impact on all aspects of the quality of life. Explain simply the current knowledge about mechanisms, contributing factors, treatment and prognosis.

**Treatment** A multidisciplinary approach to patients with vulvodynia is widely recommended.<sup>95,96</sup> The levels of evidence are poor, however.<sup>97</sup> Delays in diagnosis and inappropriate treatments may have a negative prognostic impact.

#### Vulval care measures

- Avoidance of irritating factors (IV, C)
- Use of emollient soap substitute (IV, C).

### Analgesic treatments

**Local pain modifiers** Local anaesthetics, e.g. 5% lidocaine ointment or 2% lidocaine gel, are mainly prescribed in patients with introital dyspareunia resulting from provoked vestibulodynia. Lidocaine should be applied 15–20 min prior to penetrative sex and washed off just before penetration (IV, C). Long-term daily use of lidocaine is commonly recommended in practice, although in one randomized controlled study, 12-week application of 5% lidocaine four times a day was not more effective than placebo in reducing vestibular pain<sup>98</sup> (I, A).

#### Others

- Botulinum toxin: not superior to placebo<sup>99</sup> (Ib, A)
- 2–6% gabapentin cream<sup>100</sup> (III, C)
- 2% amitriptyline cream<sup>101</sup> (III, C)
- 0.025–0.05% capsaicin cream<sup>102,103</sup> (III, C): use limited by topical side effect (burning).

**Oral pain modifiers** Mostly prescribed in case of unprovoked vulvodynia. Amitriptyline is a tricyclic antidepressant with

analgesic properties. Low doses of amitriptyline (titration from 5 to 25 mg daily) are widely used, although one randomized study has not confirmed the beneficial effect of this treatment in vulvodynia<sup>104</sup> (Ib, A).

Gabapentin, an anticonvulsant, is another treatment of neuropathic pain at an initial dose of 300 mg per day, with an increase up to 1200 mg<sup>105</sup> (III, B). There is little evidence for the use of pregabalin<sup>106</sup> (IIb, B).

Multilevel anaesthetic nerve blocks (caudal, pudendal)<sup>107,108</sup> (III, C)

**Neuromodulation** Transcutaneous Electrical Nerve stimulation (TENS) may be a self-administered home protocol<sup>109,110</sup> (Ib, B).

Acupuncture<sup>111</sup> (Ib, B)

**Physical therapies** Pelvic floor muscle dysfunction should be addressed in patients with vulvodynia, particularly when introital dyspareunia is present.

- Perineal manual therapy and biofeedback<sup>112</sup> (III, B): best results with physiotherapists experienced in the management of chronic vulval pain and its sexual impact (IV, C).
- Vaginal trainers<sup>113</sup> (III, B).

**Psychosexual interventions** Cognitive-behavioural therapy (CBT)<sup>114,115</sup> (III, C) is the mainstay approach and is superior to supportive psychotherapy<sup>116</sup> (Ib, A). As dyspareunia affects the sexual well-being of both the patient and her partner,<sup>117</sup> couples' CBT therapy seems a logical approach<sup>118</sup> (III, C). Mindfulness has also been used<sup>119</sup> (IV, C).

**Surgery** Vestibulectomy (posterior or total; with or without vaginal advancement to cover the defect) is usually considered a 'last resort', after failure of all the available therapeutical options.<sup>120</sup> However, the level of evidence is low<sup>121</sup> (III, C) and one study shows that, at long-term follow-up, vestibulectomy is not more effective than CBT.<sup>115,122</sup> In addition, surgery may aggravate pain related to a dysfunction in pain processing.

#### Follow-up

- Every 3 months until improvement (IV)
- Multidisciplinary long-term follow-up (IV).

## Vulval Intraepithelial Neoplasia (VIN)

### Introduction

VIN is a chronic vulval skin disorder characterized by dysplastic changes of the squamous epithelium. VIN is a premalignant lesion, although spontaneous regression has been reported.<sup>123</sup> In the last 100 years, premalignant lesions of the vulva have been described, but there always was a debate about the clinical and pathological characteristics of these lesions. The terminology has changed several times since the first description of VIN in 1922: 'dyskeratose erythroplasiiforme de la muqueuse vulvaire'.<sup>124</sup> The International Society for the Study of Vulvovaginal Disease (ISSVD) has been leading in the process of choosing new terminology for premalignant vulval lesions. The last version of the terminology was accepted by the ISSVD in 2015 (Table 1):

- Low-grade Squamous Intraepithelial Lesion (SIL) of the vulva or vulval LSIL.
- High-grade SIL of the vulva or vulval HSIL
- Vulval intraepithelial neoplasia, differentiated type (DVIN)<sup>125</sup>

### Aetiology

Using the latest ISSVD terminology, there are two premalignant vulval lesions which can lead to a squamous cell carcinoma of the vulva, namely HSIL and DVIN. These are completely different entities with respect to aetiology, malignant potential and treatment. HSIL is caused by a persistent infection with high-risk human papilloma virus (HPV). The incidence of HSIL is approximately 5 per 100 000 women per year and is increasing,<sup>129</sup> with the highest peak between 35 and 49 years.<sup>130</sup> A reason for the increased incidence may be the increase of anogenital HPV infections and/or a better diagnosis by the more liberal use of vulval biopsy. Risk factors are smoking and an immunocompromised state.

DVIN is associated with lichen sclerosus and lichen planus and has no relation with HPV. DVIN occurs mainly in elderly women and comprises less than 5% of VIN lesions. The malignant potential of DVIN is higher than that of HSIL.<sup>131,132</sup> The aetiology of DVIN is not clear.

### Symptoms and signs

See table 2.

**Table 1** Evolution of the ISSVD terminology

Friedrich (1976) <sup>126</sup>	Wilkinson <i>et al.</i> (1986) <sup>127</sup>	Sideri <i>et al.</i> (2005) <sup>128</sup>	Bornstein <i>et al.</i> (2016) <sup>125</sup>
Vulval atypia	VIN 1	Flat condyloma or HPV effect	LSIL
A. without dystrophy	Vin 2	VIN, usual type	HSIL
B. with dystrophy			
Squamous carcinoma in situ	VIN 3	VIN usual type	HSIL
	Differentiated VIN	VIN differentiated type	DVIN, differentiated-type VIN

**Table 2** Symptoms and signs

	<b>HSIL</b>	<b>DVIN</b>
Symptoms	Itching, burning, irritation Pain Psychosexual complaints Asymptomatic	Symptoms are often due to the underlying lichen sclerosus or lichen planus
Signs	Clinical appearance is very variable Plaques, whitish, erythematous, or pigmented Multifocal	Difficult to distinguish from lichen sclerosus lesions Grey-white or red lesion Roughened surface or ulceration More often unifocal than HSIL

## Complications

### HSIL and DVIN

- Development of vulval squamous cell carcinoma
- High rate of recurrence after treatment
- Psychosexual complaints

## Diagnosis

HSIL and DVIN are often a multifocal disease. It is important to take a biopsy of all lesions (mapping).

## Investigation

### HSIL

- Biopsy
- Histopathological characteristics: disorganization of squamous epithelium, cytological atypia, high nuclear/cytoplasmic ratio, mitotic figures

### DVIN

- Biopsy: histopathology is difficult
- Histopathological characteristics: hyperplasia, hyperkeratosis, parakeratosis, elongation and anastomosis of rete ridges, basal cell atypia, prominent nucleoli, atypical mitosis in basal layer, dyskeratosis, hypermaturation of rete ridges

## Management

**HSIL** Surgical treatment has been the first choice of treatment, but recurrence rates are high and there is a negative effect on quality of life and sexual function. A new treatment modality is the application of imiquimod cream, an immune response modifier with indirect antiviral and antitumour properties.<sup>133</sup>

- Surgical cold knife excision
- Laser CO2 therapy
- Loop electrosurgical procedure (LEEP)
- Imiquimod cream
- Follow-up without treatment (spontaneous regression)

**DVIN** Surgical cold knife excision

## Follow-up

Close follow-up is mandatory, life long.

### HSIL

- every 6–12 months, with annual cervical smear

### DVIN

- depends on underlying disease, but at least every 6 months

## Vaccination

Several types of therapeutic HPV vaccines have been developed showing different rates of clinical success. Today, therapeutic vaccines are not yet available for routine clinical use.

Prophylactic HPV vaccination was introduced in 2007 with the goal of reducing the incidence of cervical (pre)malignancies and to reduce other HPV-related lesions like HSIL. The quadrivalent HPV 6/11/16/18 vaccine shows prevention against HPV-16- and HPV-18-related high-grade lesions of vulva and vagina, in women who were HPV-16 or HPV-18 negative before vaccination.<sup>134</sup>

## Websites with useful patient information

British Association of Dermatologists.

[http://www.bad.org.uk/shared/get-file.ashx?id=180&site\\_mtype=document](http://www.bad.org.uk/shared/get-file.ashx?id=180&site_mtype=document)

[http://www.bad.org.uk/shared/get-file.ashx?id=113&site\\_mtype=document](http://www.bad.org.uk/shared/get-file.ashx?id=113&site_mtype=document)

International Society for the Study of Vulvo-vaginal Disease  
<http://issvd.org/wordpress/wp-content/uploads/2014/09/ContactDermatitis-2013-final.pdf>

British Contact Dermatitis Society Patient Information on specific allergens

<http://www.cutaneousallergy.org/downloads/patient/standard/>  
Proposed review date: 2020

## Acknowledgements

Useful input to the guidelines: Dr Philip Carobot, Dr Jonathan Ross.

Composition of editorial board (see: [http://www.iusti.org/regions/Europe/pdf/2013/Editorial\\_Board.pdf](http://www.iusti.org/regions/Europe/pdf/2013/Editorial_Board.pdf))

List of contributing organizations (see: [www.iusti.org/regions/Europe/euroguidelines.htm](http://www.iusti.org/regions/Europe/euroguidelines.htm))

## References

- 1 Radcliffe KW, Flew S, Poder A, Cusini M. 2012 European guideline for the organisation of a consultation for sexually transmitted infections. *Int J STD AIDS* 2012; **23**: 609–612.
- 2 Crone AM, Stewart EJ, Wojnarowska F, Powell SM. Aetiological factors in vulvar dermatitis. *J Eur Acad Dermatol Venereol* 2000; **14**: 181–186.



- 3 Jordan HF, Todd G, Sinclair W, Green RJ. Aetiopathogenesis of atopic dermatitis. *S Afr Med J* 2014; **104**: 706–709.
- 4 Lynch PJ. Lichen simplex chronicus (atopic/neurodermatitis) of the anogenital region. *Derm Ther* 2004; **17**: 8–19.
- 5 Elsner P, Wilhelm D, Maibach HI. Multiple parameter assessment of vulvar irritant contact dermatitis. *Contact Dermatitis* 1990; **25**: 20.
- 6 Dessinioti C, Katsambas A. Seborrhoeic dermatitis: etiology, risk factors and treatments: facts and controversies. *Clin Dermatol* 2013; **31**: 343–351.
- 7 Bauer A, Rodiger C, Greif C *et al.* Vulvar dermatoses-irritant and allergic contact dermatitis of the vulva. *Derm* 2005; **210**: 143.
- 8 Haverhoek E, Reid C, Gordon L *et al.* Prospective study of patch tests in patients with vulval pruritus. *Australas J Dermatol* 2008; **49**: 80–85.
- 9 Black RJ. Vulval eczema associated with propolis sensitization from topical therapies treated successfully with pimecrolimus cream. *Clin Exp Dermatol* 2005; **30**: 91–92.
- 10 Reveille JD, Conant MA, Duvic M. Human immunodeficiency virus-associated psoriasis, psoriatic arthritis, and Reiter's syndrome: a disease continuum? *Arthritis Rheum* 1990; **33**: 1574.
- 11 Meeuwis KA, de Hullu JA, de Jager ME, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: a questionnaire-based survey on a concealed skin disease in the Netherlands. *J Eur Acad Dermatol Venereol* 2010; **24**: 1425–1430.
- 12 Stoof TJ, van der Meijden WL. Psoriasis. In: van der Meijden WI, ter Harmsel WA, eds. *Vulvopathologie*. Koninklijke Van Gorcum BV, Assen, 2007: 137–146.
- 13 Farber EM, Nall L. Genital psoriasis. *Cutis* 1992; **50**: 263–266.
- 14 Christophers E, Barker JN, Griffiths CE *et al.* The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. *J Eur Acad Dermatol Venereol* 2010; **24**: 548–554.
- 15 Christophers E, Mrowietz U. Psoriasis. In Burgdorf WHC, Plewig G, Wolff HH, Landthaler M, eds. *Braun-Falco's Dermatology*, 3rd edn. Berlin, Springer Verlag, 2009: 506–526.
- 16 Menter A, Korman NJ, Elmets CA *et al.* Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. *J Am Acad Dermatol* 2009; **61**: 451–485.
- 17 Menter A, Korman NJ, Elmets CA *et al.* Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. American Academy of Dermatology. *J Am Acad Dermatol* 2009; **60**: 643–659.
- 18 Long CC, Finlay AY. The finger-tip unit—a new practical measure. *Clin Exp Dermatol* 1991; **16**: 444–447.
- 19 Zeichner J, Lebwohl M, Tangheiti E *et al.* Optimizing topical therapies for treating psoriasis: a consensus conference. *Cutis [serial online]* 2010; **86**(3 Suppl): 5–31.
- 20 van de Kerkhof PCM. Therapeutic strategies: rotational therapy and combinations. *Clin Exp Dermatol* 2001; **26**: 356–361.
- 21 Meeuwis KA, de Hullu JA, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital psoriasis: a systematic literature review on this hidden skin disease. *Acta Derm Venereol* 2011; **91**: 5–11.
- 22 Bonnetblanc J-M. Psoriasis. *Ann Dermatol Venereol* 2006; **133**: 298–299.
- 23 Kragballe K, Austad J, Barnes L *et al.* A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. *Br J Dermatol* 2006; **154**: 1155–1160.
- 24 Welsh BM, Berzins KN, Cook KA, Fairley CK. Management of common vulval conditions. *Med J Aust* 2003; **178**: 391–395.
- 25 Paulsen E, Korsholm L, Brandrup F. A double-blind, placebo controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris. *J Eur Acad Dermatol Venereol* 2005; **19**: 326–331.
- 26 Kalb RE, Bagel J, Korman NJ *et al.* National Psoriasis Foundation. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. *J Am Acad Dermatol* 2009; **60**: 120.
- 27 Guglielmetti A, Conlledo R, Bedoya J, Ianiszewski F, Correa J. Inverse Psoriasis Involving Genital Skin Folds: successful Therapy with Dapsone. *Dermatol Ther (Heidelb)* 2012; **2**: 15.
- 28 Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. *J Am Acad Dermatol* 2008; **59**: 295–315.
- 29 Lambert J. Pruritus in female patients. *Biomed Res Int* 2014. DOI: 10.1155/2014/541867
- 30 Moyal-Barracco M, Wendling J. Vulvar dermatosis. *Best Pract Res Clin Obstet Gynaecol* 2014; **28**: 946–958.
- 31 Stewart KMA. Clinical care of vulvar pruritus, with emphasis on one common cause, lichen simplex chronicus. *Dermatol Clin* 2010; **28**: 669–680.
- 32 Goldstein AT, Parneix-Spake A, McCormick CL, Burrows LJ. Pimecrolimus cream 1% for treatment of vulvar lichen simplex chronicus: an open-label, preliminary trial. *Gynecol Obstet Invest* 2007; **64**: 180–186.
- 33 Virgili A, Minghetti S, Borghi A, Corazza M. Phototherapy for vulvar lichen simplex chronicus: an 'off-label use' of a comb light device. *Photodermatol Photoimmunol Photomed* 2014; **30**: 332–334.
- 34 Corazza M, Borghi A, Minghetti S, Toni G, Virgili A. Effectiveness of silk fabric underwear as an adjuvant tool in the management of vulvar lichen simplex chronicus: results of a double-blind randomized controlled trial. *Menopause* 2015; **22**: 850–856.
- 35 Oyama N, Chan I, Neill SM *et al.* Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. *Lancet* 2003; **362**: 118–123.
- 36 Meyrick-Thomas RH, Ridley CM, McGibbon DH, Black MM. Lichen sclerosus and autoimmunity—a study of 350 women. *Br J Dermatol* 1988; **118**: 41–46.
- 37 Wallace HJ. Lichen sclerosus et atrophicus. *Trans St John's Hosp Dermatol Soc* 1971; **57**: 9–30.
- 38 Regauer S, Reich O. Early vulvar lichen sclerosus: a histological challenge. *Histopathology* 2005; **47**: 340–347.
- 39 Lee A, Bradford J, Fischer G. Long-term Management of Adult Vulvar Lichen Sclerosus: a Prospective Cohort Study of 507 Women. *JAMA Dermatol* 2015; **151**: 1061–1067.
- 40 Virgili A, Minghetti S, Borghi A, Corazza M. Long-term maintenance therapy for vulvar lichen sclerosus: the results of a randomized study comparing topical vitamin E with an emollient. *Eur J Dermatol* 2013; **23**: 189–194.
- 41 Virgili A, Borghi A, Toni G, Minghetti S, Corazza M. First randomized trial on clobetasol propionate and mometasone furoate in the treatment of vulvar lichen sclerosus: results of efficacy and tolerability. *Br J Dermatol* 2014; **171**: 388–396.
- 42 Chi CC, Kirtschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F. Topical interventions for genital lichen sclerosus (Review). *Cochrane Database Syst Rev* 2011; CD008240.
- 43 Virgili A, Minghetti S, Borghi A, Corazza M. Proactive maintenance therapy with a topical corticosteroid for vulvar lichen sclerosus: preliminary results of a randomized study. *Br J Dermatol* 2013; **168**: 1316–1324.
- 44 Funaro D, Lovett A, Leroux N, Powell J. A double-blind, randomized prospective study evaluating topical clobetasol propionate 0.05% versus topical tacrolimus 0.1% in patients with vulvar lichen sclerosus. *J Am Acad Dermatol* 2014; **71**: 84–91.
- 45 Hengge UR, Krause W, Hofmann H *et al.* Multi-centre, phase II trial on the safety and efficacy of topical tacrolimus ointment for the treatment of lichen sclerosus. *Br J Dermatol* 2006; **155**: 1021–1028.
- 46 Li Y, Xiao Y, Wang H, Li H, Luo X. Low-concentration topical tacrolimus for the treatment of anogenital lichen sclerosus in childhood: maintenance treatment to reduce recurrence. *J Pediatr Adolesc Gynecol* 2013; **26**: 239–242.



- 47 Goldstein AT, Creasey A, Pfau R, Phillips D, Burrows LJ. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosis. *J Am Acad Dermatol* 2011; **64**: 99–104.
- 48 Nissi R, Risteli J, Niemimaa M. Pimecrolimus cream 1% in the treatment of lichen sclerosis. *Gynecol Obstet Invest* 2006; **63**: 151–154.
- 49 Edey K, Bisson D, Kennedy C. Topical tacrolimus in the management of lichen sclerosis. *Br J Obstet Gynaecol* 2006; **113**: 1482.
- 50 Fischer G, Bradford J. Topical immunosuppressants, genital lichen sclerosis and the risk of squamous cell carcinoma. *J Reprod Med* 2007; **52**: 329–331.
- 51 Bousema MT, Romppanen U, Geiger JM *et al.* Acitretin in the treatment of severe lichen sclerosis et atrophicus of the vulva: a double-blind, placebo controlled study. *J Am Acad Dermatol* 1994; **30**: 225–231.
- 52 Ioannides D, Lazaridou E, Apalla Z, Sotiriou E, Gregoriou S, Rigopoulos D. Acitretin for severe lichen sclerosis of male genitalia: a randomized, placebo controlled study. *J Urol* 2010; **183**: 1395–1399.
- 53 Ormerod AD, Campalani E, Goodfield MJD. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. *Br J Dermatol* 2010; **162**: 952–963.
- 54 Beattie PE, Dawe RS, Ferguson J, Ibbotson SH. UVA1 phototherapy for genital lichen sclerosis. *Clin Exp Dermatol* 2006; **31**: 343–347.
- 55 Terras S, Gambichler T, Moritz RKC, Stücker M, Kreuter A. Ultraviolet-A1 Phototherapy versus Clobetasol Propionate, 0.05%, in the Treatment of Vulvar Lichen Sclerosis – A Randomized Clinical Trial. *JAMA Dermatol* 2014; **150**: 621–627.
- 56 Abramov Y, Elchalal U, Abramov D, Goldfarb A, Schenker JG. Surgical treatment of vulvar lichen sclerosis: a review. *Obstet Gynecol Surv* 1996; **51**: 193–199. Review.
- 57 Kreuter A, Gambichler T, Saueremann K *et al.* Extragenital lichen sclerosis successfully treated with topical calcipotriol: evaluation by in vivo confocal laser scanning microscopy. *Br J Dermatol* 2002; **146**: 332–333.
- 58 Cooper SM, Dean D, Allen J *et al.* Erosive lichen planus of the vulva: weak circulating basement membrane zone antibodies are present. *Clin Exp Dermatol* 2005; **30**: 551–556.
- 59 Marren P, Millard P, Chia Y *et al.* Mucosal lichen sclerosis/lichen planus overlap syndromes. *Br J Dermatol* 1994; **131**: 118–123.
- 60 Lewis FM, Shah M, Harrington CI. Vulval involvement in lichen planus: a study of 37 women. *Br J Dermatol* 1996; **135**: 89–91.
- 61 Cooper SM, Wojnarowska F. Influence of treatment of erosive lichen planus of the vulva on its prognosis. *Arch Dermatol* 2006; **142**: 289–294.
- 62 Genadry R, Provost TT. Severe vulvar scarring in patients with erosive lichen planus. *J Reprod Med* 2006; **51**: 67–72.
- 63 Simpson RC, Thomas KS, Leighton P, Murphy R. Diagnostic criteria for erosive lichen planus affecting the vulva: an international electronic-Delphi consensus exercise. *Br J Dermatol* 2013; **169**: 337–343.
- 64 Regauer S, Reich O, Eberz B. Vulvar cancers in women with vulvar lichen planus: a clinicopathological study. *J Am Acad Dermatol* 2014; **71**: 698–707.
- 65 Borghi A, Corazza M, Minghetti S, Virgilli A. Preliminary study on dermoscopic features of vulvar lichen planus: new insights for diagnosis. *J Eur Acad Dermatol Venereol* 2016; **30**: 1063–1065.
- 66 Kirtschig G, Wakelin SH, Wojnarowska F. Mucosal vulval lichen planus: outcome, clinical and laboratory features. *J Eur Acad Dermatol Venereol* 2005; **19**: 301–307.
- 67 Cooper SM, Kirtschig G, Jeffery KJM, Wojnarowska K. No association between hepatitis B or C viruses and vulval lichen planus in a UK population. *Br J Obstet Gynaecol* 2004; **111**: 271–273.
- 68 Cheng S, Kirtschig G, Cooper S *et al.* Interventions for erosive lichen planus affecting mucosal sites. *Cochrane Database Syst Rev* 2012; **2**: CD008092.
- 69 Helgesen AL, Warloe T, Pripp AH *et al.* Vulvovaginal photodynamic therapy vs. topical corticosteroids in genital erosive lichen planus: a randomized controlled trial. *Br J Dermatol* 2015; **173**: 1156–1162.
- 70 Goldstein AT, Thaci D, Luger T. Topical calcineurin inhibitors for the treatment of vulvar dermatosis. *Eur J Obstet Gynecol Reprod Biol* 2009; **146**: 22–29.
- 71 Byrd JA, Davis MD, Rogers RD 3rd. Recalcitrant symptomatic vulvar lichen planus: response to topical tacrolimus. *Arch Dermatol* 2004; **140**: 715–720.
- 72 Bradford J, Fischer G. Management of vulvovaginal lichen planus: a new approach. *J Low Genit Tract Dis* 2013; **17**: 28–32.
- 73 Wee JS, Shirlaw PJ, Challacombe SJ, Setterfield JF. Efficacy of mycophenolate mofetil in severe mucocutaneous lichen planus: a retrospective review of 10 patients. *Br J Dermatol* 2012; **167**: 36–43.
- 74 Deen K, McMeniman E. Mycophenolate mofetil in erosive genital lichen planus: a case and review of the literature. *J Dermatol* 2015; **42**: 311–314.
- 75 Worsnop F, Wee J, Natkunarajah J, Moosa Y, Marsden R. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus. *Clin Exp Dermatol* 2012; **37**: 879–881.
- 76 Reborá A, Parodi A, Marialdo G. Basiliximab is effective for erosive lichen planus. *Arch Dermatol* 2002; **138**: 1100–1111.
- 77 Stalburg CM, Haefner HK. Vaginal stenosis in lichen planus. Surgical treatment tips for patients in whom conservative therapies have failed. *J Pelvic Med Surg* 2008; **14**: 193–198.
- 78 Suzuki V, Haefner HK, Piper CK, O’Gara C, Reed BD. Postoperative sexual concerns and functioning in patients who underwent lysis of vulvovaginal adhesions. *J Low Genit Tract Dis* 2013; **17**: 33–37.
- 79 Moyal-Barracco M, Lynch PJ. 2003 ISSVD terminology and classification of vulvodynia: a historical perspective. *J Reprod Med* 2004; **49**: 772–777.
- 80 Pukall CF, Binik YM, Khalife S, Amsel R, Abbott FV. Vestibular tactile and pain thresholds in women with vulvar vestibulitis syndrome. *Pain* 2002; **96**: 163–175.
- 81 Hampson JP, Reed BD, Clauw DJ *et al.* Augmented central pain processing in vulvodynia. *J Pain* 2013; **14**: 579–589.
- 82 Hoffman D. Central and Peripheral Pain Generators in Women with Chronic Pelvic Pain: patient Centered Assessment and Treatment. *Curr Rheumatol Rev* 2015; **11**: 146–166.
- 83 Reed BD, Harlow SD, Sen A, Edwards RM, Chen D, Haefner HK. Relationship between vulvodynia and chronic comorbid pain conditions. *Obstet Gynecol* 2012; **120**: 145–151.
- 84 Nguyen RH, Veasley C, Smolenski D. Latent class analysis of comorbidity patterns among women with generalized and localized vulvodynia: preliminary findings. *J Pain Res* 2013; **6**: 303–309.
- 85 Heddini U, Bohm-Starke N, Grönlund A, Nyberg F, Nilsson KW, Johannesson U. Serotonin receptor gene (5HT-2A) polymorphism is associated with provoked vestibulodynia and comorbid symptoms of pain. *J Sex Med* 2014; **11**: 3064–3071.
- 86 Falsetta ML, Foster DC, Woeller CF *et al.* Identification of novel mechanisms involved in generating localized vulvodynia pain. *Am J Obstet Gynecol* 2015; **213**: 38.e1–12.
- 87 Landry T, Bergeron S. Biopsychosocial factors associated with dyspareunia in a community sample of adolescent girls. *Arch Sex Behav* 2011; **40**: 877–889.
- 88 Harlow BL, Stewart EG. Adult-onset vulvodynia in relation to childhood violence victimization. *Am J Epidemiol* 2005; **161**: 871–880.
- 89 Khandker M, Brady SS, Vitonis AF, Macle hose RF, Stewart EG, Harlow BL. The influence of depression and anxiety on risk of adult onset vulvodynia. *J Womens Health (Larchmt)* 2011; **20**: 1445–1451.
- 90 Hartmann D. Chronic vulvar pain from a physical therapy perspective. *Dermatol Ther* 2010; **23**: 505–513.

- 91 Reed BD, Haefner HK, Sen A, Gorenflo DW. Vulvodynia incidence and remission rates among adult women: a 2-year follow-up study. *Obstet Gynecol* 2008; **112**: 231–237.
- 92 Nguyen RH, Mathur C, Wynings EM, Williams DA, Harlow BL. Remission of vulvar pain among women with primary vulvodynia. *J Low Genit Tract Dis* 2015; **19**: 62–67.
- 93 Gardella B, Porru D, Nappi RE, Daccò MD, Chiesa A, Spinillo A. Interstitial cystitis is associated with vulvodynia and sexual dysfunction—a case-control study. *J Sex Med* 2011; **8**: 1726–1734.
- 94 Bergeron S, Likes WM, Steben M. Psychosexual aspects of vulvovaginal pain. *Best Pract Res Clin Obstet Gynaecol* 2014; **28**: 991–999.
- 95 Edwards SK, Bates CM, Lewis F, Sethi G, Grover D. 2014 UK national guideline on the management of vulval conditions. *Int J STD AIDS* 2015; **26**: 611–624.
- 96 Brotto LA, Yong P, Smith KB, Sadownik LA. Impact of a multidisciplinary vulvodynia program on sexual functioning and dyspareunia. *J Sex Med* 2015; **12**: 238–247.
- 97 Andrews JC. Vulvodynia interventions—systematic review and evidence grading. *Obstet Gynecol Surv* 2011; **66**: 299–315.
- 98 Foster DC, Kotok MB, Huang LS *et al.* Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial. *Obstet Gynecol* 2010; **116**: 583–593.
- 99 Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A—a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. *J Sex Med* 2009; **6**: 2523–2537.
- 100 Boardman LA, Cooper AS, Blais LR, Raker CA. Topical gabapentin in the treatment of localized and generalized vulvodynia. *Obstet Gynecol* 2008; **112**: 579–585.
- 101 Pagano R, Wong S. Use of amitriptyline cream in the management of entry dyspareunia due to provoked vestibulodynia. *J Low Genit Tract Dis* 2012; **16**: 394–397.
- 102 Murina F, Radici G, Bianco V. Capsaicin and the treatment of vulvar vestibulitis syndrome: a valuable alternative? *MedGenMed* 2004; **6**: 48.
- 103 Steinberg AC, Oyama IA, Rejba AE, Kellogg-Spadt S, Whitmore KE. Capsaicin for the treatment of vulvar vestibulitis. *Am J Obstet Gynecol* 2005; **192**: 1549–1553.
- 104 Brown CS, Wan J, Bachmann G, Rosen R. Self-management, amitriptyline, and amitriptyline plus triamcinolone in the management of vulvodynia. *J Womens Health (Larchmt)* 2009; **18**: 163–169.
- 105 Spoelstra SK, Borg C, Weijmar Schultz WC. Anticonvulsant pharmacotherapy for generalized and localized vulvodynia: a critical review of the literature. *J Psychosom Obstet Gynaecol* 2013; **34**: 133–138.
- 106 Jerome L. Pregabalin-induced remission in a 62-year-old woman with a 20-year history of vulvodynia. *Pain Res Manag* 2007; **12**: 212–214.
- 107 McDonald JS, Rapkin AJ. Multilevel local anesthetic nerve blockade for the treatment of generalized vulvodynia: a pilot study. *J Sex Med* 2012; **9**: 2919–2926.
- 108 Rapkin AJ, McDonald JS, Morgan M. Multilevel local anesthetic nerve blockade for the treatment of vulvar vestibulitis syndrome. *Am J Obstet Gynecol* 2008; **198**: 41.e1–5. Epub 2007 Oct 22. PubMed PMID: 17936236.
- 109 Murina F, Bianco V, Radici G, Felice R, Di Martino M, Nicolini U. Transcutaneous electrical nerve stimulation to treat vestibulodynia: a randomised controlled trial. *BJOG* 2008; **115**: 1165–1170.
- 110 Murina F, Graziottin A, Felice R, Radici G, Tognocchi C. Vestibulodynia: synergy between palmitoylethanolamide + transpolydatin and transcutaneous electrical nerve stimulation. *J Low Genit Tract Dis* 2013; **17**: 111–116.
- 111 Schlaeger JM, Xu N, Mejta CL, Park CG, Wilkie DJ. Acupuncture for the treatment of vulvodynia: a randomized wait-list controlled pilot study. *J Sex Med* 2015; **12**: 1019–1027.
- 112 Murina F, Bernorio R, Palmiotto R. The use of amielle vaginal trainers as adjuvant in the treatment of vestibulodynia: an observational multicentric study. *Medscape J Med* 2008; **10**: 23.
- 113 Gentilcore-Saulnier E, McLean L, Goldfinger C, Pukall CF, Chamberlain S. Pelvic floor muscle assessment outcomes in women with and without provoked vestibulodynia and the impact of a physical therapy program. *J Sex Med* 2010; **7**: 1003–1022.
- 114 ter Kuile MM, Weijnenborg PT. A cognitive-behavioral group program for women with vulvar vestibulitis syndrome (VVS): factors associated with treatment success. *J Sex Marital Ther* 2006; **32**: 199–213.
- 115 Bergeron S, Binik YM, Khalifé S *et al.* A randomized comparison of group cognitive-behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. *Pain* 2001; **91**: 297–306.
- 116 Masheb RM, Kerns RD, Lozano C, Minkin MJ, Richman S. A randomized clinical trial for women with vulvodynia: Cognitive-behavioral therapy vs. supportive psychotherapy. *Pain* 2009; **141**: 31–40.
- 117 Lemieux AJ, Bergeron S, Steben M, Lambert B. Do romantic partners' responses to entry dyspareunia affect women's experience of pain? The roles of catastrophizing and self-efficacy. *J Sex Med* 2013; **10**: 2274–2284.
- 118 Corsini-Munt S, Bergeron S, Rosen NO, Mayrand MH, Delisle I. Feasibility and preliminary effectiveness of a novel cognitive-behavioral couple therapy for provoked vestibulodynia: a pilot study. *J Sex Med* 2014; **11**: 2515–2527.
- 119 Basson R. The recurrent pain and sexual sequelae of provoked vestibulodynia: a perpetuating cycle. *J Sex Med* 2012; **9**: 2077–2092.
- 120 Stockdale CK, Lawson HW. 2013 Vulvodynia Guideline update. *J Low Genit Tract Dis* 2014; **18**: 93–100.
- 121 De Andres J, Sanchis-Lopez N, Asensio-Samper JM *et al.* Vulvodynia—An evidence-based literature review and proposed treatment algorithm. *Pain Pract* 2016; **16**: 204–236.
- 122 Bergeron S, Khalifé S, Glazer HI, Binik YM. Surgical and behavioral treatments for vestibulodynia: two-and-one-half year follow-up and predictors of outcome. *Obstet Gynecol* 2008; **111**: 159–166.
- 123 Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. *Obstet Gynecol* 2005; **106**: 1319–1326.
- 124 Hudelo ML, Oury C. Dyskeratose erythroplasiiforme de la musqueuse vulvaire. *Bull Soc Franc Dermatol Et Syph* 1922; **29**: 139–142.
- 125 Bornstein J, Bogliatto F, Haefner HK *et al.* The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) Terminology of vulvar Squamous Intraepithelial Lesions. *J Lower Gen Tract Dis* 2016; **20**: 11–14.
- 126 Friedrich EG. Report of the committee on terminology. New nomenclature for vulvar disease. *Obstet Gynecol* 1976; **49**: 122–124.
- 127 Wilkinson EJ, Kneale B, Lynch PJ. Report of the ISSVD terminology committee. *Reprod Med* 1986; **31**: 973–974.
- 128 Sideri M, Jones RW, Wilkinson EJ *et al.* Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. *J Reprod Med* 2005; **50**: 807–810.
- 129 Joura EA. Epidemiology, diagnosis and treatment of vulvar intraepithelial neoplasia. *Curr Opin Obstet Gynecol* 2002; **14**: 39–43.
- 130 Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. *Obstet Gynecol* 2006; **107**: 1018–1022.
- 131 Roma AA, Hart WR. Progression of simplex (differentiated) vulvar intraepithelial neoplasia to invasive squamous cell carcinoma: a prospective case study confirming its precursor role in the pathogenesis of vulvar cancer. *Int J Gynecol Pathol* 2007; **26**: 248–253.
- 132 Van de Nieuwenhof HP, van der Avoort IA, de Hullu JA. Review of squamous premalignant vulvar lesions. *Crit Rev Oncol Hematol* 2008; **68**: 131–156.

- 133 Van Seters M, van Beurden M, ten Kate F *et al.* Treatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod. *N Engl J Med* 2008; **358**: 1465–1473.
- 134 Joura EA, Leodolter S, Hernandez-Avila M *et al.* Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. *Lancet* 2007; **369**: 1693–1702.

## Appendices

### Search strategy

Searched libraries: MEDLINE, MEDLINE process, Embase, Cochrane library. Sexually transmitted diseases guidelines

produced by the British Association for Sexual Health and HIV ([www.bashh.org](http://www.bashh.org)) were also reviewed.

Search up to March 2015 with no date limitation. The search strategy comprised the following terms in the title or abstract: Vulval lichen sclerosus, Vulval lichen planus, Vulval eczema, Vulval lichen simplex, Vulval psoriasis, Vulval intraepithelial neoplasia, Vulval pain syndromes/vulvodynia.

### Tables of levels of evidence and grading of recommendations

(see: [http://www.iusti.org/regions/Europe/pdf/2013/Levels\\_of\\_Evidence.pdf](http://www.iusti.org/regions/Europe/pdf/2013/Levels_of_Evidence.pdf))